Skip to contentC
CytomX Therapeutics, Inc.
C
CTMXCytomX Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$9.19M$9.19M+23.1% vs Q3 2020 Net Income-$22.58M-$22.58MN/M vs Q3 2020 EPS Diluted-$0.48-$0.48N/M vs Q3 2020 Operating Income-$22,641,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CytomX Therapeutics, Inc. · CIK 1501989 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$29,968,000N/M Margins · derivedOperating margin-246.4%−46.9 pt vs Q3 2020
Net margin-245.8%−48.7 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 4, 2021 · 35 d after period end